DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

DexCom (NASDAQ: DXCM ... may be skeptical about that playing such a huge role in its ability to grow its revenue. The question marks and uncertainty about that is a reason why it might be better ...

Today we will run through one way of estimating the intrinsic value of DexCom, Inc. ( NASDAQ:DXCM) by estimating the company's future cash flows and discounting them to their present value. The ...

DexCom blames its restructuring ... may be skeptical about that playing such a huge role in its ability to grow its revenue. The question marks and uncertainty about that is a reason why it ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its Lingo device - and ...

Android 15 was launched a few months ago, and discussion is already turning to Android 16, which is currently in the testing ...

Now that we're a month out from CES, these are the trends that have stuck with me. Yes, AI is on the list, of course, but so ...

The On-Body Drug Delivery Devices market is witnessing significant growth, driven by the increasing demand for ...

The global glucose monitoring devices market was valued at USD 14.1 billion in 2023 and is expected to grow to USD 15.67 ...

Medtronic's stock lags peers due to growth challenges in the diabetes and hypertension markets. See why we recommend a sell ...